Cybin (HELP) Cash from Investing Activities (2020 - 2026)
Cybin (HELP) posted quarterly Cash from Investing Activities of -$323000.0 for Q1 2026, up 57.24% year-on-year from -$205412.7 in Q1 2025, and up 15.67% on a QoQ basis from -$383000.0 in Q4 2025.
Cybin (HELP) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Cybin (HELP) has reported Cash from Investing Activities for 7 consecutive years, with -$323000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities rose 57.24% year-over-year to -$323000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 2.4% YoY) and the FY2026 annual result came in at -$1.4 million, up 2.36% from the prior year.
- Cash from Investing Activities climbed to -$323000.0 in Q1 2026 per HELP's latest filing, from -$383000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for HELP reached as high as $5.5 million in Q4 2023 and fell as low as -$2.1 million in Q3 2022.
- A 5-year average of $7136.4 and a median of -$217000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 2835.02% — and 2023, when it jumped 3693.26%.
- Year by year, Cash from Investing Activities stood at -$152497.5 in 2022, then soared by 3693.26% to $5.5 million in 2023, then sank by 103.96% to -$217000.0 in 2024, then tumbled by 76.5% to -$383000.0 in 2025, then gained by 15.67% to -$323000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$323000.0, -$383000.0, and -$436000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -45.51 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 178,242.27 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 172.62 Mn |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | -323,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -323,000.00 |
| Mar 31, 2026 | -323,000.00 |
| Dec 31, 2025 | -383,000.00 |
| Dec 31, 2025 | -383,000.00 |
| Sep 30, 2025 | -436,000.00 |
| Sep 30, 2025 | -436,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Mar 31, 2025 | -755,457.46 |
| Mar 31, 2025 | -755,457.46 |
| Dec 31, 2024 | -217,000.00 |
| Dec 31, 2024 | -217,000.00 |
| Sep 30, 2024 | -251,000.00 |
| Sep 30, 2024 | -251,000.00 |
| Jun 30, 2024 | -173,000.00 |
| Jun 30, 2024 | -173,000.00 |
| Mar 31, 2024 | -159,554.34 |
| Mar 31, 2024 | -159,554.34 |
| Dec 31, 2023 | 5.48 Mn |
| Dec 31, 2023 | 5.48 Mn |